Zydus Therapeutics
Trial Pipeline
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
NCT06825559
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT06427395
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT05045482
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835
Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function
NCT04469920
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
NCT03863574
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
NCT03112681
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
NCT03061721
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 4 |
| Phase 3 | 1 |
What the Pipeline for Zydus Therapeutics Shows
According to the ClinicalTrials.gov registry, Zydus Therapeutics is linked to 36 US clinical trials across every stage of research activity. Of those, 31 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Zydus Therapeutics reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 35 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Zydus Therapeutics is Hepatic Impairment with 2 linked trials, and 8 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.